Mer­ck’s snap­shot of pos­i­tive da­ta for front­line lung can­cer niche trig­gers a new scram­ble for quick Keytru­da OK

Mer­ck has caught the big wave on front­line lung can­cer, and it plans to ride an ear­ly pos­i­tive sig­nal straight through to a quick OK for an­oth­er lu­cra­tive mar­ket niche for Keytru­da.

This morn­ing the phar­ma gi­ant post­ed word that their Keynote-407 tri­al scored a pos­i­tive hit on the over­all re­sponse rate for un­treat­ed metasta­t­ic squa­mous non-small cell lung can­cer in an in­ter­im analy­sis and they’ve al­ready filed for the ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER